Payment overview · 2025
General Payments
$203.40
11 reported records · 6 companies
Healthcare provider profile · identity verified
Timothy Stephen Mcafee, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAWRENCEBURG, IN · NPI 1548851785
Verified facts
What the public records show
CMS Open Payments records show Timothy Stephen Mcafee, APRN received $203.40 in general payments during 2025 across 11 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Viberzi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.55 | 30.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.21 | 26.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.83 | 18.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.89 | 10.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.32 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.60 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.40 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.55 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.21 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 421 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 35 |
| Gabapentin | Gabapentin | 224 | 12 |
| Furosemide | Furosemide | 198 | 18 |
| Metformin Hcl | Metformin Hcl | 182 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | suppressed |
| Famotidine | Famotidine | 134 | suppressed |
| Mirtazapine | Mirtazapine | 134 | 15 |
| Fentanyl | Fentanyl | 104 | suppressed |
| Spironolactone | Spironolactone | 94 | suppressed |
| Lisinopril | Lisinopril | 92 | suppressed |
| Lacosamide | Lacosamide | 76 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Lorazepam | Lorazepam | 71 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 16 |
| Carvedilol | Carvedilol | 67 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | suppressed |
| Omeprazole | Omeprazole | 61 | suppressed |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Prednisone | Prednisone | 56 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 24 |
| Eliquis | Apixaban | 53 | suppressed |
| Creon | Lipase/Protease/Amylase | 52 | suppressed |
| Tradjenta | Linagliptin | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 17 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | suppressed |
| Viberzi | Eluxadoline | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Nystatin | Nystatin | 15 | 11 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.40 · 11 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, CAPLYTA, COMIRNATY, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error